Back to Search
Start Over
Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Dec 28; Vol. 60 (3), pp. 1600-7. Date of Electronic Publication: 2015 Dec 28. - Publication Year :
- 2015
-
Abstract
- The choice of an antimicrobial agent must balance optimization of efficacy endpoints with the minimization of safety events. The risk versus benefit of daptomycin for patients with Staphylococcus aureus bacteremia with or without infective endocarditis receiving daptomycin at 6, 8, and 10 mg/kg of body weight/day was assessed. The relationships between the area under the concentration-time curve over 24 h (AUC)/MIC ratio and both clinical response and time to decreased susceptibility were evaluated using data from patients with such infections who received daptomycin at 6 mg/kg/day. Using these relationships, plus the previously identified relationship between the minimum concentration and an elevation in the creatine phosphokinase (CPK) concentration (CPK elevation) (S. M. Bhavnani, C. M. Rubino, P. G. Ambrose, and G. L. Drusano, Clin Infect Dis 50:1568-1574, 2010) and Monte Carlo simulation, the probability of each outcome by MIC for daptomycin at 6, 8, and 10 mg/kg/day was calculated. The function for exposure-response relationships for clinical response (P = 0.06) and time to decreased susceptibility (P = 0.01) resembled U and inverted U shapes, respectively. Multivariable analyses demonstrated AUC/MIC ratio, creatinine clearance, albumin concentration, and disease category to be predictors of clinical response. The results of simulations failed to demonstrate large improvements in the probabilities of clinical success among cohorts of simulated patients defined by the above-described predictive factors or the probability of decreased susceptibility at 30 days when the daptomycin dose was increased from 6 to 10 mg/kg/day. The probability of CPK elevation increased from 0.073 to 0.156 over this dose range. These data can be used to inform risk-versus-benefit decisions for daptomycin dose selection in patients with S. aureus bacteremia with or without infective endocarditis. The risk of CPK elevation, which is reversible, should be weighed in the context of the mortality and severe morbidity associated with these types of serious staphylococcal infections.<br /> (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents adverse effects
Area Under Curve
Bacteremia microbiology
Creatine Kinase blood
Creatinine blood
Daptomycin adverse effects
Endocarditis, Bacterial microbiology
Female
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Monte Carlo Method
Risk
Serum Albumin analysis
Staphylococcal Infections microbiology
Staphylococcus aureus drug effects
Treatment Outcome
Young Adult
Anti-Bacterial Agents therapeutic use
Bacteremia drug therapy
Daptomycin therapeutic use
Endocarditis, Bacterial drug therapy
Risk Assessment
Staphylococcal Infections drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 60
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 26711755
- Full Text :
- https://doi.org/10.1128/AAC.02967-15